FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

Spectrum Pharmaceuticals, Inc.
Trademark Policy

All Contents © Spectrum Pharmaceuticals, Inc. 2017. All rights reserved.

The tradenames, trademarks, service marks, logos, icons and trade dress of Spectrum Pharmaceuticals, Inc., appearing on this website may not be used in any manner by users of this website without the express prior written permission of Spectrum Pharmaceuticals, Inc. Such tradenames, trademarks, service marks, logos, icons and trade dress, include, without limitation, SPECTRUM PHARMACEUTICALS, INC.®, FOLOTYN®, the Spectrum Pharmaceuticals and the FOLOTYN® logos, which are all trademarks owned by Spectrum Pharmaceuticals, Inc. and its subsidiaries. All non-Spectrum owned trademarks, tradenames and service marks are the property of their respective owners.